Minerva Neurosciences, Inc. — Q1 2022 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing roluperidone for negative symptoms of schizophrenia and MIN-301 for Parkinson’s disease. It has no approved products and reported no product revenue. Results cover the three months ended March 31, 2022; the financial statements are unaudited.
Financial results and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | None | None from product sales or licensing |
| Research and development expense | $5.0 million | $3.3 million; up about $1.7 million, primarily NDA-support consulting |
| General and administrative expense | $3.0 million | $4.2 million; down about $1.2 million, mainly lower staffing, stock compensation, legal and insurance costs |
| Operating loss | $8.0 million | $7.5 million |
| Net loss | $9.8 million; $0.23 per share | $8.8 million; $0.21 per share |
| Operating cash used | $5.8 million | $5.2 million |
| Cash, cash equivalents and restricted cash | $55.0 million at March 31 | $60.9 million at December 31, 2021 |
There are no meaningful commercial margins to report. The company had total assets of $70.6 million and total liabilities of $71.4 million, including a $68.1 million liability associated with the sale of future seltorexant royalties. Stockholders’ equity was negative $0.7 million. This royalty-related obligation is accounted for as debt under the applicable accounting guidance; the former term loans were repaid in 2018. The obligation increased by $1.8 million in the quarter from non-cash interest expense. No shares were issued under the ATM program in Q1; 42.7 million shares were outstanding at March 31.
Material changes and cash resources
Net loss increased by about $1.0 million year over year. Higher R&D expense and royalty-obligation interest more than offset lower G&A. Cash declined by $5.8 million in Q1 2022, with no financing proceeds; Q1 2021 included the $60 million upfront royalty-sale payment. Management expects existing cash to cover commitments for at least 12 months after issuance of the financial statements, but says additional capital will be needed to continue operations and fully fund potential later-stage development. Financing availability and terms are not assured; failure to obtain funding could require scaling back or discontinuing operations.
Outlook, clinical update and risks
- After quarter-end, the company reported FDA feedback from a March 2, 2022 Type C meeting. The FDA reiterated substantial concerns about roluperidone, including the Phase 3 evidence, use of post hoc analyses, applicability of Phase 2b results to U.S. patients, and patient selection and symptom monitoring. The Division had previously indicated a marketing application was highly unlikely to be filed without two adequate and well-controlled trials.
- The company maintains that its studies support an application and, subject to FDA timing and feedback, continued preparing for a potential roluperidone NDA submission in Q3 2022. The FDA said additional data collection could proceed alongside preparation. The filing does not establish that an NDA will be accepted or approved.
- The Phase 3 study remained negative overall, according to the FDA. Excluding a site the company believes had potential data-integrity issues yielded a nominal p-value of 0.044 for the 64 mg dose; the 32 mg dose did not meet the described statistical requirement. The company said the site exclusion was prespecified.
- The company expects continued operating losses and negative operating cash flow. Clinical, regulatory and commercialization costs, trial outcomes, access to capital, and COVID-19-related disruption could materially affect its plans and financial condition.
- Nasdaq had notified the company of a minimum-bid-price deficiency, with a July 11, 2022 deadline to regain compliance, and a separate stockholders’ equity deficiency. The company anticipated submitting a compliance plan and was seeking stockholder approval for a possible reverse split. Continued listing was not assured.
The filing reports that a consolidated securities class action concerning roluperidone disclosures was voluntarily dismissed and the case closed in July 2021. No damages were quantified in the complaints.
Important facts for investors to verify
- Subsequent FDA interactions, additional-data requirements, and whether an NDA was submitted, accepted, or approved.
- Actual cash burn and financing needs relative to the stated 12-month liquidity expectation.
- Progress on Nasdaq bid-price and stockholders’ equity compliance, including any reverse split or other capital actions.
- Changes in the royalty-obligation estimate and interest expense, which depend on assumptions about seltorexant development, approval and future sales.
- Clinical development timelines and any impact from trial execution, service-provider disruption, or public-health and geopolitical risks.